Exagen INC 10-Q quarterly reports

Exagen Inc. announced a 15.9% increase in revenue for the second quarter of 2026, driven by higher test volumes and an expanded AVISE CTD platform, alongside improved gross margins.

Exagen Inc. reported an 11.7% increase in revenue for the first quarter of 2026, driven by biomarker enhancements and a growing average selling price.

Exagen Inc. announced significant revenue growth and improved operational cash flow in its third-quarter 2025 results, driven by increased test volumes and new biomarker launches, while also securing substantial new financing.

Exagen Inc. reported a 14.2% increase in revenue for the second quarter of 2025, driven by new biomarker launches and higher test volumes, despite experiencing a significant rise in net losses and operating expenses.

Exagen Inc. announces its financial results for the first quarter of 2025, highlighting a 7.5% increase in revenue compared to the same period last year and securing a new term loan facility.

Exagen Inc. reported a 6.8% decrease in revenue for the third quarter of 2024 compared to the same period in 2023, alongside a net loss of $5.0 million.

Exagen Inc. saw a revenue increase in the second quarter of 2024 compared to the same period last year, while also reducing its net losses.

Exagen Inc. saw a 28.4% increase in revenue and a significant reduction in net loss for the first quarter of 2024 compared to the same period last year.